Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer

NCT01639885 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Ovarian Cancer

Interventions

DRUG: Interferon Alfa-2b
DRUG: Interferon Alfa-2b
BIOLOGICAL: p53 SLP

Sponsor

Leiden University Medical Center

Collaborators

[object Object]